Company & Sponsor Intelligence

Stony Brook University

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials7

Recruiting2

Completed3

Countries1

Therapeutic footprint

adhdalsanxietyautismdepressionstroke

Indexed studies

NCT07559461Fear and Anxiety in Anesthesia-Naïve Patients Pre-operatively vs Post-operatively
anxiety · United StatesRECRUITING

NCT04459455Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic
anxiety · United StatesNA

NCT04208425Promoting Resilience in Teens With ASD
autism · United StatesNA

NCT03320018Neuroprotection in Acute Ischemic Stroke
stroke · United StatesPHASE2, PHASE3

NCT03020797A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)
als · United StatesNA

NCT00441649Methylphenidate for Treating Children With ADHD and Tourette Syndrome
adhd · NA

NCT07076342The Role of mGluR5 in CBT-I
depression · United StatesPHASE4

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →